Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1671992

Cover Image

PUBLISHER: Persistence Market Research | PRODUCT CODE: 1671992

Antibiotic Resistance Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
PDF & Excel (Multi User License)
USD 7295
PDF & Excel (Corporate User License)
USD 8495

Add to Cart

Description

Table of Contents

Persistence Market Research has recently released a comprehensive report on the worldwide market for antibiotic resistance. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global antibiotic resistance market from 2025 to 2032.

Key Insights:

  • Antibiotic Resistance Market Size (2025E): US$ 11.8 Bn
  • Projected Market Value (2032F): US$ 17.08 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032):5.4%

Antibiotic Resistance Market - Report Scope:

Antibiotic resistance is a growing global health crisis caused by the overuse and misuse of antibiotics, leading to the emergence of drug-resistant bacteria. This market encompasses diagnostics, novel antibiotic development, alternative therapies, and antimicrobial stewardship programs aimed at combating resistance. The demand for innovative antibiotics, rapid diagnostic tests, and non-traditional treatments, such as bacteriophage therapy and antimicrobial peptides, is driving market growth. The antibiotic resistance market serves pharmaceutical companies, biotechnology firms, healthcare providers, and research institutions, addressing the urgent need for effective solutions against multidrug-resistant infections.

Market Growth Drivers:

The global antibiotic resistance market is propelled by several key factors, including the rising prevalence of drug-resistant infections, the increasing burden of hospital-acquired infections, and the growing emphasis on antimicrobial stewardship programs. The development of rapid diagnostic tools for early detection of resistant pathogens is accelerating market adoption. Government initiatives and funding for antibiotic research, along with regulatory incentives such as fast-track approvals and market exclusivity, further boost market growth. Additionally, advancements in biotechnology, including the use of AI-driven drug discovery and microbiome-based therapies, present new opportunities for tackling resistance effectively.

Market Restraints:

Despite promising growth prospects, the antibiotic resistance market faces challenges related to high research and development costs, stringent regulatory requirements, and limited return on investment for new antibiotic development. The slow adoption of alternative therapies and the lack of awareness regarding antimicrobial resistance in low- and middle-income countries hinder market expansion. Moreover, the reluctance of pharmaceutical companies to invest in antibiotic R&D due to lower profitability compared to chronic disease drugs poses a challenge to market growth. Addressing these challenges requires global collaboration, financial incentives, and increased public-private partnerships to support antibiotic innovation.

Market Opportunities:

The antibiotic resistance market presents significant growth opportunities driven by novel drug development, personalized medicine approaches, and the integration of digital health technologies. The rising demand for combination therapies, next-generation sequencing (NGS) for pathogen identification, and AI-driven predictive analytics for antimicrobial resistance management are reshaping the market landscape. Public health initiatives promoting responsible antibiotic use and global funding programs supporting antimicrobial innovation create additional opportunities for stakeholders. Strengthening international collaboration between healthcare organizations, research institutes, and pharmaceutical companies will be crucial in accelerating market expansion and combating the global threat of antibiotic resistance.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the antibiotic resistance market globally?
  • Which product segments are leading market adoption, and what role do novel antibiotics and alternative therapies play?
  • How are technological advancements reshaping the competitive landscape of the antibiotic resistance market?
  • Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global antibiotic resistance market?

Competitive Intelligence and Business Strategy:

Leading players in the global antibiotic resistance market, including Pfizer Inc., Merck & Co., GlaxoSmithKline plc, and Paratek Pharmaceuticals, are focusing on innovation, strategic partnerships, and regulatory approvals to gain a competitive edge. These companies are investing in research and development for next-generation antibiotics, bacteriophage therapy, and precision medicine-based antimicrobial solutions. Collaborations with government agencies, non-profit organizations, and biotech startups facilitate market access and accelerate the development of novel treatments. Moreover, emphasis on clinical trials, antimicrobial stewardship programs, and public awareness campaigns fosters market growth and strengthens global efforts to combat antibiotic resistance.

Key Companies Profiled:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Paratek Pharmaceuticals, Inc.
  • Entasis Therapeutics
  • Melinta Therapeutics, Inc.
  • Tetraphase Pharmaceuticals, Inc.
  • Achaogen, Inc.
  • Nabriva Therapeutics plc
  • Basilea Pharmaceutica Ltd.

Antibiotic Resistance Industry Segmentation

By Drug Class

  • Beta Lactam Antibiotic
  • Tetracyclines
  • Lipoglycopeptides
  • Combination Therapies
  • Cephalosporins
  • Oxazolidinones

By Pathogen

  • Staphylococcus aureus
  • Streptococcus pneumonia
  • Vancomycin- resistant Enterococcus
  • Neisseria gonorrhoeae
  • Pseudomonas aeruginosa
  • Escherichia coli
  • Mycobacterium tuberculosis
  • Acinetobacter
  • Clostridium difficile

By Disease

  • Community Acquired Bacterial Pneumonia (CABP)
  • Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
  • Complicated Urinary Tract Infections (CUTI)
  • Complicated Intra- Abdominal Infections (CIAI)
  • Blood Stream Infections (BSI)
  • Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

By Mechanism of Action

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa
  • Latin America
Show more
Product Code: PMRREP27895

Table of Contents

1. Executive Summary

  • 1.1. Global Antibiotic Resistance Market Snapshot, 2025 and 2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Disease Epidemiology
  • 3.3. Pipeline Analysis
  • 3.4. Product Adoption Analysis
  • 3.5. Value Chain Analysis
  • 3.6. Key Promotional Strategies by Manufacturers
  • 3.7. PESTLE Analysis
  • 3.8. Porter's Five Force Analysis

4. Global Antibiotic Resistance Market Outlook:

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn ) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn ) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn ) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn ) Analysis and Forecast, 2025-2032
  • 4.3. Global Antibiotic Resistance Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn ) Analysis, By Drug Class, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
      • 4.3.3.1. Beta Lactam Antibiotic
      • 4.3.3.2. Tetracyclines
      • 4.3.3.3. Lipoglycopeptides
      • 4.3.3.4. Combination Therapies
      • 4.3.3.5. Cephalosporins
      • 4.3.3.6. Oxazolidinones
      • 4.3.3.7. Others
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Antibiotic Resistance Market Outlook: Pathogen
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn ) Analysis, By Pathogen, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
      • 4.4.3.1. Staphylococcus aureus
      • 4.4.3.2. Streptococcus pneumonia
      • 4.4.3.3. Vancomycin- resistant Enterococcus
      • 4.4.3.4. Neisseria gonorrhoeae
      • 4.4.3.5. Pseudomonas aeruginosa
      • 4.4.3.6. Escherichia coli
      • 4.4.3.7. Mycobacterium tuberculosis
      • 4.4.3.8. Acinetobacter
      • 4.4.3.9. Clostridium difficile
      • 4.4.3.10. Others
    • 4.4.4. Market Attractiveness Analysis: Pathogen
  • 4.5. Global Antibiotic Resistance Market Outlook: Disease
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn ) Analysis, By Disease, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
      • 4.5.3.1. Community Acquired Bacterial Pneumonia (CABP)
      • 4.5.3.2. Hopitals Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
      • 4.5.3.3. Complicated Urinary Tract Infections (CUTI)
      • 4.5.3.4. Complicated Intra- Abdominal Infections (CIAI)
      • 4.5.3.5. Blood Stream Infections (BSI)
      • 4.5.3.6. Abdominal Infection and Diarohhea (Clostridium difficile infections (CDI) & Shigella)
      • 4.5.3.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
      • 4.5.3.8. Others
    • 4.5.4. Market Attractiveness Analysis: Disease
  • 4.6. Global Antibiotic Resistance Market Outlook: Mechanism of Action
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn ) Analysis, By Mechanism of Action, 2019-2024
    • 4.6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
      • 4.6.3.1. Cell Wall Synthesis Inhibitors
      • 4.6.3.2. Protein Synthesis Inhibitors
      • 4.6.3.3. DNA Synthesis Inhibitors
      • 4.6.3.4. RNA Synthesis Inhibitors
      • 4.6.3.5. Others
    • 4.6.4. Market Attractiveness Analysis: Mechanism of Action
  • 4.7. Global Antibiotic Resistance Market Outlook: Distribution Channel
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn ) Analysis, By Distribution Channel, 2019-2024
    • 4.7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
      • 4.7.3.1. Hospitals Pharmacies
      • 4.7.3.2. Retail Pharmacies
      • 4.7.3.3. Online Pharmacies
    • 4.7.4. Market Attractiveness Analysis: Distribution Channel

5. Global Antibiotic Resistance Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn ) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Antibiotic Resistance Market Outlook:

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Pathogen
    • 6.2.4. By Disease
    • 6.2.5. By Mechanism of Action
    • 6.2.6. By Distribution Channel
  • 6.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 6.4.1. Beta Lactam Antibiotic
    • 6.4.2. Tetracyclines
    • 6.4.3. Lipoglycopeptides
    • 6.4.4. Combination Therapies
    • 6.4.5. Cephalosporins
    • 6.4.6. Oxazolidinones
    • 6.4.7. Others
  • 6.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 6.5.1. Staphylococcus aureus
    • 6.5.2. Streptococcus pneumonia
    • 6.5.3. Vancomycin- resistant Enterococcus
    • 6.5.4. Neisseria gonorrhoeae
    • 6.5.5. Pseudomonas aeruginosa
    • 6.5.6. Escherichia coli
    • 6.5.7. Mycobacterium tuberculosis
    • 6.5.8. Acinetobacter
    • 6.5.9. Clostridium difficile
    • 6.5.10. Others
  • 6.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 6.6.1. Community Acquired Bacterial Pneumonia (CABP)
    • 6.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 6.6.3. Complicated Urinary Tract Infections (CUTI)
    • 6.6.4. Complicated Intra- Abdominal Infections (CIAI)
    • 6.6.5. Blood Stream Infections (BSI)
    • 6.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
    • 6.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 6.6.8. Others
  • 6.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 6.7.1. Cell Wall Synthesis Inhibitors
    • 6.7.2. Protein Synthesis Inhibitors
    • 6.7.3. DNA Synthesis Inhibitors
    • 6.7.4. RNA Synthesis Inhibitors
    • 6.7.5. Others
  • 6.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 6.8.1. Hospitals Pharmacies
    • 6.8.2. Retail Pharmacies
    • 6.8.3. Online Pharmacies
  • 6.9. Market Attractiveness Analysis

7. Europe Antibiotic Resistance Market Outlook:

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Pathogen
    • 7.2.4. By Disease
    • 7.2.5. By Mechanism of Action
    • 7.2.6. By Distribution Channel
  • 7.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 7.4.1. Beta Lactam Antibiotic
    • 7.4.2. Tetracyclines
    • 7.4.3. Lipoglycopeptides
    • 7.4.4. Combination Therapies
    • 7.4.5. Cephalosporins
    • 7.4.6. Oxazolidinones
    • 7.4.7. Others
  • 7.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 7.5.1. Staphylococcus aureus
    • 7.5.2. Streptococcus pneumonia
    • 7.5.3. Vancomycin- resistant Enterococcus
    • 7.5.4. Neisseria gonorrhoeae
    • 7.5.5. Pseudomonas aeruginosa
    • 7.5.6. Escherichia coli
    • 7.5.7. Mycobacterium tuberculosis
    • 7.5.8. Acinetobacter
    • 7.5.9. Clostridium difficile
    • 7.5.10. Others
  • 7.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 7.6.1. Community Acquired Bacterial Pneumonia (CABP)
    • 7.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 7.6.3. Complicated Urinary Tract Infections (CUTI)
    • 7.6.4. Complicated Intra- Abdominal Infections (CIAI)
    • 7.6.5. Blood Stream Infections (BSI)
    • 7.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
    • 7.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 7.6.8. Others
  • 7.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 7.7.1. Cell Wall Synthesis Inhibitors
    • 7.7.2. Protein Synthesis Inhibitors
    • 7.7.3. DNA Synthesis Inhibitors
    • 7.7.4. RNA Synthesis Inhibitors
    • 7.7.5. Others
  • 7.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 7.8.1. Hospitals Pharmacies
    • 7.8.2. Retail Pharmacies
    • 7.8.3. Online Pharmacies
  • 7.9. Market Attractiveness Analysis

8. East Asia Antibiotic Resistance Market Outlook:

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Pathogen
    • 8.2.4. By Disease
    • 8.2.5. By Mechanism of Action
    • 8.2.6. By Distribution Channel
  • 8.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 8.4.1. Beta Lactam Antibiotic
    • 8.4.2. Tetracyclines
    • 8.4.3. Lipoglycopeptides
    • 8.4.4. Combination Therapies
    • 8.4.5. Cephalosporins
    • 8.4.6. Oxazolidinones
    • 8.4.7. Others
  • 8.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 8.5.1. Staphylococcus aureus
    • 8.5.2. Streptococcus pneumonia
    • 8.5.3. Vancomycin- resistant Enterococcus
    • 8.5.4. Neisseria gonorrhoeae
    • 8.5.5. Pseudomonas aeruginosa
    • 8.5.6. Escherichia coli
    • 8.5.7. Mycobacterium tuberculosis
    • 8.5.8. Acinetobacter
    • 8.5.9. Clostridium difficile
    • 8.5.10. Others
  • 8.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 8.6.1. Community Acquired Bacterial Pneumonia (CABP)
    • 8.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 8.6.3. Complicated Urinary Tract Infections (CUTI)
    • 8.6.4. Complicated Intra- Abdominal Infections (CIAI)
    • 8.6.5. Blood Stream Infections (BSI)
    • 8.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
    • 8.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 8.6.8. Others
  • 8.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 8.7.1. Cell Wall Synthesis Inhibitors
    • 8.7.2. Protein Synthesis Inhibitors
    • 8.7.3. DNA Synthesis Inhibitors
    • 8.7.4. RNA Synthesis Inhibitors
    • 8.7.5. Others
  • 8.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 8.8.1. Hospitals Pharmacies
    • 8.8.2. Retail Pharmacies
    • 8.8.3. Online Pharmacies
  • 8.9. Market Attractiveness Analysis

9. South Asia & Oceania Antibiotic Resistance Market Outlook:

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Pathogen
    • 9.2.4. By Disease
    • 9.2.5. By Mechanism of Action
    • 9.2.6. By Distribution Channel
  • 9.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 9.4.1. Beta Lactam Antibiotic
    • 9.4.2. Tetracyclines
    • 9.4.3. Lipoglycopeptides
    • 9.4.4. Combination Therapies
    • 9.4.5. Cephalosporins
    • 9.4.6. Oxazolidinones
    • 9.4.7. Others
  • 9.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 9.5.1. Staphylococcus aureus
    • 9.5.2. Streptococcus pneumonia
    • 9.5.3. Vancomycin- resistant Enterococcus
    • 9.5.4. Neisseria gonorrhoeae
    • 9.5.5. Pseudomonas aeruginosa
    • 9.5.6. Escherichia coli
    • 9.5.7. Mycobacterium tuberculosis
    • 9.5.8. Acinetobacter
    • 9.5.9. Clostridium difficile
    • 9.5.10. Others
  • 9.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 9.6.1. Community Acquired Bacterial Pneumonia (CABP)
    • 9.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 9.6.3. Complicated Urinary Tract Infections (CUTI)
    • 9.6.4. Complicated Intra- Abdominal Infections (CIAI)
    • 9.6.5. Blood Stream Infections (BSI)
    • 9.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
    • 9.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 9.6.8. Others
  • 9.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 9.7.1. Cell Wall Synthesis Inhibitors
    • 9.7.2. Protein Synthesis Inhibitors
    • 9.7.3. DNA Synthesis Inhibitors
    • 9.7.4. RNA Synthesis Inhibitors
    • 9.7.5. Others
  • 9.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 9.8.1. Hospitals Pharmacies
    • 9.8.2. Retail Pharmacies
    • 9.8.3. Online Pharmacies
  • 9.9. Market Attractiveness Analysis

10. Latin America Antibiotic Resistance Market Outlook:

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Pathogen
    • 10.2.4. By Disease
    • 10.2.5. By Mechanism of Action
    • 10.2.6. By Distribution Channel
  • 10.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 10.4.1. Beta Lactam Antibiotic
    • 10.4.2. Tetracyclines
    • 10.4.3. Lipoglycopeptides
    • 10.4.4. Combination Therapies
    • 10.4.5. Cephalosporins
    • 10.4.6. Oxazolidinones
    • 10.4.7. Others
  • 10.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 10.5.1. Staphylococcus aureus
    • 10.5.2. Streptococcus pneumonia
    • 10.5.3. Vancomycin- resistant Enterococcus
    • 10.5.4. Neisseria gonorrhoeae
    • 10.5.5. Pseudomonas aeruginosa
    • 10.5.6. Escherichia coli
    • 10.5.7. Mycobacterium tuberculosis
    • 10.5.8. Acinetobacter
    • 10.5.9. Clostridium difficile
    • 10.5.10. Others
  • 10.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 10.6.1. Community Acquired Bacterial Pneumonia (CABP)
    • 10.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 10.6.3. Complicated Urinary Tract Infections (CUTI)
    • 10.6.4. Complicated Intra- Abdominal Infections (CIAI)
    • 10.6.5. Blood Stream Infections (BSI)
    • 10.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
    • 10.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 10.6.8. Others
  • 10.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 10.7.1. Cell Wall Synthesis Inhibitors
    • 10.7.2. Protein Synthesis Inhibitors
    • 10.7.3. DNA Synthesis Inhibitors
    • 10.7.4. RNA Synthesis Inhibitors
    • 10.7.5. Others
  • 10.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 10.8.1. Hospitals Pharmacies
    • 10.8.2. Retail Pharmacies
    • 10.8.3. Online Pharmacies
  • 10.9. Market Attractiveness Analysis

11. Middle East & Africa Antibiotic Resistance Market Outlook:

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn ) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Pathogen
    • 11.2.4. By Disease
    • 11.2.5. By Mechanism of Action
    • 11.2.6. By Distribution Channel
  • 11.3. Current Market Size (US$ Bn ) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn ) Analysis and Forecast, By Drug Class, 2025-2032
    • 11.4.1. Beta Lactam Antibiotic
    • 11.4.2. Tetracyclines
    • 11.4.3. Lipoglycopeptides
    • 11.4.4. Combination Therapies
    • 11.4.5. Cephalosporins
    • 11.4.6. Oxazolidinones
    • 11.4.7. Others
  • 11.5. Current Market Size (US$ Bn ) Analysis and Forecast, By Pathogen, 2025-2032
    • 11.5.1. Staphylococcus aureus
    • 11.5.2. Streptococcus pneumonia
    • 11.5.3. Vancomycin- resistant Enterococcus
    • 11.5.4. Neisseria gonorrhoeae
    • 11.5.5. Pseudomonas aeruginosa
    • 11.5.6. Escherichia coli
    • 11.5.7. Mycobacterium tuberculosis
    • 11.5.8. Acinetobacter
    • 11.5.9. Clostridium difficile
    • 11.5.10. Others
  • 11.6. Current Market Size (US$ Bn ) Analysis and Forecast, By Disease, 2025-2032
    • 11.6.1. Community Acquired Bacterial Pneumonia (CABP)
    • 11.6.2. Hospital Acquired Bacterial Pneumonia/ Ventilator (HABP/VABP)
    • 11.6.3. Complicated Urinary Tract Infections (CUTI)
    • 11.6.4. Complicated Intra- Abdominal Infections (CIAI)
    • 11.6.5. Blood Stream Infections (BSI)
    • 11.6.6. Abdominal Infection and Diarrhea (Clostridium difficile infections (CDI) & Shigella)
    • 11.6.7. Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
    • 11.6.8. Others
  • 11.7. Current Market Size (US$ Bn ) Analysis and Forecast, By Mechanism of Action, 2025-2032
    • 11.7.1. Cell Wall Synthesis Inhibitors
    • 11.7.2. Protein Synthesis Inhibitors
    • 11.7.3. DNA Synthesis Inhibitors
    • 11.7.4. RNA Synthesis Inhibitors
    • 11.7.5. Others
  • 11.8. Current Market Size (US$ Bn ) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 11.8.1. Hospitals Pharmacies
    • 11.8.2. Retail Pharmacies
    • 11.8.3. Online Pharmacies
  • 11.9. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Thermo Fisher Scientific, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Merck KgaA
    • 12.3.3. Bio-Rad Laboratories, Inc.
    • 12.3.4. Takara Bio, Inc.
    • 12.3.5. QIAGEN N.V.
    • 12.3.6. Pall Corporation
    • 12.3.7. Eppendorf Corporate
    • 12.3.8. Tarsons Products PVT. LTD.
    • 12.3.9. Applied Biological Materials Inc.
    • 12.3.10. Greiner AG
    • 12.3.11. Brooks Life Sciences
    • 12.3.12. Corning Incorporated
    • 12.3.13. Cytiva
    • 12.3.14. PerkinElmer

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!